{"id":"naproxen","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Dyspepsia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Heartburn","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Ecchymosis","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Skin eruptions","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Tinnitus","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Stomatitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Lightheadedness","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Palpitations","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Alcoholism","Anemia","Angina pectoris","Angle-closure glaucoma","Atrophic gastritis","Benign prostatic hyperplasia","Blood coagulation disorder","Body fluid retention","Cardiovascular event risk","Cerebral ischemia","Cerebrovascular accident","Chronic heart failure","Coronary arteriosclerosis","Coronary artery bypass graft","Diabetes mellitus","Disease of liver","Disorder of cardiovascular system","Disorder of coronary artery","Edema","Epilepsy","Esophageal dysmotility","Fracture of bone","Gastrointestinal hemorrhage","Gastrointestinal perforation","Gastrointestinal ulcer","Hemiplegic migraine","Hepatic failure","Hypercholesterolemia","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Hypomagnesemia","Hypovolemia","Kidney disease","Liver function tests abnormal","Myocardial infarction","Myocardial ischemia","Obesity","Osteoporosis","Peripheral vascular disease","Pregnancy, function","Prinzmetal angina","Retention of urine","Serotonin syndrome","Smokes tobacco daily","Tachyarrhythmia","Thromboembolic disorder","Transient ischemic attack","Vascular insufficiency of intestine"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Gross bleeding/perforation","drugRate":"5.5%","severity":"serious"},{"effect":"GI ulcers","drugRate":"5.5%","severity":"serious"},{"effect":"Pancreatitis","drugRate":"0.5%","severity":"serious"},{"effect":"Jaundice","drugRate":"0.5%","severity":"serious"},{"effect":"Melena","drugRate":"0.5%","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"0.5%","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"0.5%","severity":"serious"},{"effect":"Vomiting","drugRate":"5%","severity":"serious"},{"effect":"Abnormal renal function","drugRate":"5.5%","severity":"serious"},{"effect":"Anemia","drugRate":"5.5%","severity":"serious"}]},"status":"approved","trials":["NCT01165307","NCT07487909","NCT06916234","NCT00750243","NCT03493945","NCT01916395","NCT00442208","NCT01267825","NCT05237297","NCT00720057","NCT01417130","NCT02152592","NCT02549469","NCT00626275","NCT07173231","NCT00913627","NCT04307940","NCT01688934","NCT00602420","NCT01951105","NCT00170898","NCT00780325","NCT00830063","NCT02502006","NCT07493226","NCT00772967","NCT00153660","NCT00643799","NCT01207115","NCT01053507","NCT00137033","NCT01331993","NCT03654326","NCT05411718","NCT04463420","NCT01016678","NCT00969449","NCT01052129","NCT01358383","NCT02611466","NCT03658473","NCT02229461","NCT02528188","NCT01086358","NCT02108548","NCT00650455","NCT00843024","NCT00596245","NCT02262754","NCT06274151"],"aliases":["Naprosyn","Anaprox","Aleve"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.5917/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$213","description":"NAPROXEN 125 MG/5 ML SUSPEN","retrievedDate":"2026-04-07"}],"allNames":"aleve","offLabel":[],"timeline":[],"aiSummary":"Naproxen is a long-acting NSAID first approved in 1976, now available OTC as Aleve and generically worldwide. Its 12-17 hour half-life allows convenient twice-daily dosing and it has the most favorable cardiovascular safety profile among NSAIDs.","brandName":"Aleve","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","novelty":"","modality":"Small molecule","drugClass":"NSAID","explanation":"Naproxen is a long-acting NSAID with a half-life of 12-17 hours, allowing twice-daily dosing. It inhibits both cyclooxygenase isoforms, reducing prostaglandin production. Among NSAIDs, naproxen has shown the most favorable cardiovascular safety profile in large meta-analyses, making it a preferred choice for patients with cardiovascular risk factors who require anti-inflammatory therapy.","oneSentence":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Generic (originally Syntex)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"naproxen","indications":{"approved":[{"name":"Ankylosing spondylitis","diseaseId":"ankylosing-spondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bursitis","diseaseId":"bursitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dysmenorrhea","diseaseId":"dysmenorrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Fever","diseaseId":"fever","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gout","diseaseId":"gout","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Headache disorder","diseaseId":"headache-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Joint pain","diseaseId":"joint-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Juvenile rheumatoid arthritis","diseaseId":"juvenile-rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Migraine","diseaseId":"migraine","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Muscle pain","diseaseId":"muscle-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal discharge","diseaseId":"nasal-discharge","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteoarthritis","diseaseId":"osteoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pain","diseaseId":"pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sinus headache","diseaseId":"sinus-headache","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tendinitis","diseaseId":"tendinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Toothache","diseaseId":"toothache","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01165307","phase":"Phase 4","title":"A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis","status":"COMPLETED","sponsor":"Abimbola Famuyide","isPivotal":false,"enrollment":77,"indication":"Menorrhagia","completionDate":"2015-10"},{"nctId":"NCT07487909","phase":"Phase 1","title":"A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of SJP-001 in Comparison With Fexofenadine and Naproxen Administered ","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","isPivotal":false,"enrollment":47,"indication":"Healthy","completionDate":"2025-11-21"},{"nctId":"NCT06916234","phase":"Phase 4","title":"Evaluation of the Analgesic Efficacy of the Combination of Dexketoprofen + Paracetamol and the Combination of Naproxen Sodium + Codeine in Patients With Acute Dental Pain","status":"COMPLETED","sponsor":"ibrahim doğru","isPivotal":false,"enrollment":100,"indication":"Acute Dental Pain","completionDate":"2024-01-20"},{"nctId":"NCT00750243","phase":"Phase 1","title":"A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation","status":"COMPLETED","sponsor":"Logical Therapeutics","isPivotal":false,"enrollment":120,"indication":"Healthy","completionDate":"2009-04"},{"nctId":"NCT03493945","phase":"Phase 1","title":"A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":59,"indication":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","completionDate":"2024-10-08"},{"nctId":"NCT01916395","phase":"N/A","title":"Comparison of Treximet and Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache.","status":"COMPLETED","sponsor":"Gary E. Ruoff, M.D.","isPivotal":false,"enrollment":30,"indication":"Migraine","completionDate":"2011-07"},{"nctId":"NCT00442208","phase":"Phase 1","title":"","status":"COMPLETED","sponsor":"POZEN","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2008-02"},{"nctId":"NCT01267825","phase":"Phase 4","title":"A Randomized Trial of CT-guided Perineural Injection With a Corticosteroid Plus a Long Acting Local Anesthetic Versus Standard Medical Management in Patients With Acute Lumbar Radiculopathy and a Corr","status":"TERMINATED","sponsor":"Montefiore Medical Center","isPivotal":false,"enrollment":1,"indication":"Disc Herniation, Lumbosacral Radiculopathy","completionDate":"2013-08"},{"nctId":"NCT05237297","phase":"Phase 1","title":"A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interactions and Safety After Co-administration of Ilaprazole and NSAID in Healthy Adults","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","isPivotal":false,"enrollment":72,"indication":"Drug Interaction Potentiation","completionDate":"2022-07-27"},{"nctId":"NCT00720057","phase":"Phase 3","title":"A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental","status":"COMPLETED","sponsor":"Bayer","isPivotal":true,"enrollment":312,"indication":"Toothache","completionDate":"2008-08"},{"nctId":"NCT01417130","phase":"N/A","title":"Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study","status":"UNKNOWN","sponsor":"Seattle Institute for Biomedical and Clinical Research","isPivotal":false,"enrollment":1650,"indication":"Alzheimer Disease, Dementia","completionDate":"2012-08"},{"nctId":"NCT02152592","phase":"Phase 4","title":"Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Maastricht University Medical Center","isPivotal":false,"enrollment":105,"indication":"Postoperative Pain After Ambulatory Surgery","completionDate":""},{"nctId":"NCT02549469","phase":"Phase 1","title":"A Pilot Four-Way Crossover Bioequivalence Trial of Sustained Release Forms of Naproxen Versus Aleve Tablets in Healthy Adult Subjects in a Fasted State","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":32,"indication":"Pain","completionDate":"2007-05"},{"nctId":"NCT00626275","phase":"Phase 2","title":"A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Effica","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","isPivotal":false,"enrollment":46,"indication":"Rheumatoid Arthritis","completionDate":"2008-09"},{"nctId":"NCT07173231","phase":"NA","title":"Comparisons Between Virtual Reality and Hypno-Virtual Reality for Procedural Pain and Anxiety During a Diagnostic Hysteroscopy: A Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"St. Justine's Hospital","isPivotal":false,"enrollment":45,"indication":"Hysteroscopy, Anxiety","completionDate":"2026-03"},{"nctId":"NCT00913627","phase":"Phase 2","title":"Ibuprofen 600 Mg Extended Release (er) Single-dose Dental Pain Study","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":196,"indication":"Pain","completionDate":"2009-08-05"},{"nctId":"NCT04307940","phase":"Phase 4","title":"A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Hydrocodone/Acetaminophen Tablets in Postsurgical Dental Pain","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":221,"indication":"Pain","completionDate":"2020-10-05"},{"nctId":"NCT01688934","phase":"Phase 2","title":"A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chron","status":"COMPLETED","sponsor":"Purdue Pharma LP","isPivotal":false,"enrollment":230,"indication":"Osteoarthritis, Knee, Pain","completionDate":"2013-08"},{"nctId":"NCT00602420","phase":"Phase 3","title":"Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Gary Morrow","isPivotal":true,"enrollment":510,"indication":"Musculoskeletal Complications, Pain","completionDate":"2012-03"},{"nctId":"NCT01951105","phase":"Phase 4","title":"Corticostriatal Plasticity in the Transition to Chronic Pain: Effect of L-dopa","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":72,"indication":"Sub-acute Back Pain","completionDate":"2017-09-25"},{"nctId":"NCT00170898","phase":"Phase 4","title":"A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Ac","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":419,"indication":"Musculoskeletal Pain","completionDate":""},{"nctId":"NCT00780325","phase":"Phase 1","title":"A Single Center, Double-blind, Placebo-controlled Phase I Single-dose Cross-over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on t","status":"TERMINATED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":26,"indication":"Healthy Volunteers","completionDate":"2013-07"},{"nctId":"NCT00830063","phase":"Phase 3","title":"A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":832,"indication":"Arthritis, Osteoarthritis","completionDate":"2010-08-31"},{"nctId":"NCT02502006","phase":"Phase 1","title":"A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs","status":"TERMINATED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2022-09"},{"nctId":"NCT07493226","phase":"NA","title":"Comparative Efficacy of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) With Distinct Chemical Structures in Shoulder Adhesive Capsulitis and the Role of Pain Phenotypes","status":"RECRUITING","sponsor":"Konya Beyhekim Training and Research Hospital","isPivotal":false,"enrollment":120,"indication":"Frozen Shoulder, Adhesive Capsulitis","completionDate":"2027-03-30"},{"nctId":"NCT00772967","phase":"Phase 1","title":"A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen and Ultracet in a Walking Model of Osteoarthritis Knee Pain","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":22,"indication":"Osteoarthritis","completionDate":"2008-11"},{"nctId":"NCT00153660","phase":"Phase 3","title":"A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","isPivotal":true,"enrollment":514,"indication":"Arthritis, Cardiovascular Diseases","completionDate":"2016-12"},{"nctId":"NCT00643799","phase":"Phase 4","title":"A Randomized, Multicenter, Double-Blind, Double-Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-month Treatment of Subje","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":586,"indication":"Osteoarthritis, Knee","completionDate":"2005-01"},{"nctId":"NCT01207115","phase":"Phase 2","title":"A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Osteoarthritis Pain of the Knee","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":322,"indication":"Osteoarthritis of the Knee","completionDate":"2011-05"},{"nctId":"NCT01053507","phase":"Phase 4","title":"Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction","status":"TERMINATED","sponsor":"Cady, Roger, M.D.","isPivotal":false,"enrollment":23,"indication":"Post-Traumatic Headache","completionDate":"2012-11"},{"nctId":"NCT00137033","phase":"Phase 4","title":"A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects ","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":605,"indication":"Peptic Ulcers","completionDate":"2005-07"},{"nctId":"NCT01331993","phase":"Phase 1","title":"A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOV","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":36,"indication":"Healthy Volunteers, Bioequivalence","completionDate":"2011-10"},{"nctId":"NCT03654326","phase":"Phase 2","title":"A Phase 2a, Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women With Moderate to Severe Endometriosis-Related Pain","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":187,"indication":"Endometriosis-related Pain","completionDate":"2020-06-30"},{"nctId":"NCT05411718","phase":"Phase 2","title":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":40,"indication":"T Cells, Colorectal Cancer","completionDate":"2026-11-30"},{"nctId":"NCT04463420","phase":"NA","title":"Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study","status":"UNKNOWN","sponsor":"Baqiyatallah Medical Sciences University","isPivotal":false,"enrollment":224,"indication":"COVID-19","completionDate":"2020-12-15"},{"nctId":"NCT01016678","phase":"Phase 2","title":"Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate Efficacy & Safety of ComboProduct Containing Sumatriptan and Naproxen Sodium for Acu","status":"COMPLETED","sponsor":"Premiere Research Institute","isPivotal":true,"enrollment":104,"indication":"Migraine","completionDate":"2014-07"},{"nctId":"NCT00969449","phase":"Phase 1","title":"An Open Label, Randomized, Two-Way Crossover Trial to Compare the Pharmacokinetic Parameters of an Extended- Release Naproxen Sodium Tablet Relative to Naprelan® Tablets Following Single Dose Administ","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":28,"indication":"Pharmacokinetics","completionDate":"2009-05"},{"nctId":"NCT01052129","phase":"Phase 1","title":"Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, ","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2006-05"},{"nctId":"NCT01358383","phase":"Phase 1","title":"A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":28,"indication":"Juvenile Idiopathic Arthritis","completionDate":"2011-06"},{"nctId":"NCT02611466","phase":"Phase 2","title":"A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","isPivotal":false,"enrollment":215,"indication":"Osteoarthritis of the Knee, Chronic Lower Back Pain","completionDate":"2017-09-29"},{"nctId":"NCT03658473","phase":"Phase 3","title":"Double-blind, Phase III Study to Evaluate Gastroprotection Obtained by the Use of Rebamipide 300 mg (2x Daily) and Rabeprazole 20 mg/Day (1x Daily) Associated or Not to Prevent Naproxen (1100 mg/Day)-","status":"COMPLETED","sponsor":"Galeno Desenvolvimento de Pesquisas Clínicas","isPivotal":true,"enrollment":32,"indication":"Gastric Lesion","completionDate":"2015-02-04"},{"nctId":"NCT02229461","phase":"Phase 1","title":"A Randomized, Open Label, Parallel Group Study to Investigate the Effects on Serum Thromboxane by the Addition of Naproxen Sodium to Aspirin Therapy Versus Aspirin Therapy Alone","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":117,"indication":"Hematology","completionDate":"2015-05"},{"nctId":"NCT02528188","phase":"Phase 3","title":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR ","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":3021,"indication":"Chronic Pain, Osteoarthritis, Hip","completionDate":"2019-02-27"},{"nctId":"NCT01086358","phase":"Phase 4","title":"A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan","status":"COMPLETED","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":60,"indication":"Workplace Migraine Treatment","completionDate":"2016-08"},{"nctId":"NCT02108548","phase":"Phase 1","title":"A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy ","status":"TERMINATED","sponsor":"Astellas Pharma Europe B.V.","isPivotal":false,"enrollment":89,"indication":"Pharmacokinetics of ASP7657, Pharmacodynamics of ASP7657","completionDate":"2015-03"},{"nctId":"NCT00650455","phase":"Phase 4","title":"Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Tre","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":489,"indication":"Arthritis, Rheumatoid","completionDate":"2005-01"},{"nctId":"NCT00843024","phase":"Phase 3","title":"TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Tre","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":589,"indication":"Migraine Disorders","completionDate":"2010-06"},{"nctId":"NCT00596245","phase":"Phase 1","title":"Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets Administered Two Hours Apart on Chromosomal Aberratio","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":42,"indication":"Healthy","completionDate":"2007-12"},{"nctId":"NCT02262754","phase":"Phase 2","title":"A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of Pf-06372865 In Subjects With Chronic L","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":302,"indication":"Chronic Low Back Pain","completionDate":"2015-08"},{"nctId":"NCT06274151","phase":"NA","title":"Optimal Treatment of Inflammation Following Acute Skeletal Muscle Injury","status":"NOT_YET_RECRUITING","sponsor":"Bispebjerg Hospital","isPivotal":false,"enrollment":20,"indication":"Muscle Strain, Multiple Sites, Inflammation","completionDate":"2029-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Every 8-12 hours","formulation":"Tablet, Delayed-release tablet, Liquid"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"1976-01-01","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}